Get our Free Patent Expiration, Litigation, and Drug Price Updates

Serving hundreds of leading biopharmaceutical companies globally:

Cipla
UBS
Medtronic
Deloitte
US Department of Justice
QuintilesIMS

Generated: May 25, 2019

DrugPatentWatch Database Preview

Terbinafine - Generic Drug Details

« Back to Dashboard

What are the generic drug sources for terbinafine and what is the scope of terbinafine patent protection?

Terbinafine is the generic ingredient in three branded drugs marketed by Glaxosmithkline Cons, Glaxosmithkline, Novartis, Taro, Apotex, Aurobindo Pharma, Breckenridge Pharm, Cipla, Dr Reddys Labs Inc, Gedeon Richter Usa, Glenmark Generics, Harris Pharm, Invagen Pharms, Mylan, Orchid Hlthcare, Roxane, Teva, and Wockhardt, and is included in twenty-four NDAs. Additional information is available in the individual branded drug profile pages.

There are twenty-seven drug master file entries for terbinafine. There are four tentative approvals for this compound.

Synonyms for terbinafine
((E)-6,6-Dimethyl-hept-2-en-4-ynyl)-methyl-naphthalen-1-ylmethyl-amine
(2E)-N,6,6-trimethyl-N-(1-naphthylmethyl)hept-2-en-4-yn-1-amine
(2E)-N,6,6-trimethyl-N-(naphthalen-1-ylmethyl)hept-2-en-4-yn-1-amine
(2E)-N,6,6-Trimethyl-N-(naphthalen-1-ylmethyl)hept-2-en-4-yn-1-amine (HCl)
(6,6-Dimethyl-hept-2-en-4-ynyl)-methyl-naphthalen-1-ylmethyl-amine
(6,6-Dimethyl-hept-2-en-4-ynyl)-methyl-naphthalen-1-ylmethyl-amine(Terbinafine)
(6,6-dimethylhept-2-en-4-yn-1-yl)methyl(1-naphthylmethyl)amine hydrochloride
(E)-N-(6,6-Dimethyl-2-hepten-4-ynyl)-N-methyl-1-naphthalene methanamine
(E)-N-(6,6-Dimethyl-2-hepten-4-ynyl)-N-methyl-1-naphthalenemethylamine
(E)-N-(6,6-dimethyl-2-heptenynyl)-N-methyl-1-naphthalenementhamin hydrochloride
(E)-N,6,6-trimethyl-N-(1-naphthalenylmethyl)-1-hept-2-en-4-ynamine
(E)-N,6,6-trimethyl-N-(1-naphthylmethyl)hept-2-en-4-yn-1-amine
(E)-N,6,6-trimethyl-N-(naphthalen-1
(E)-N,6,6-trimethyl-N-(naphthalen-1-ylmethyl)hept-2-en-4-yn-1-amine
[(2E)-6,6-dimethylhept-2-en-4-yn-1-yl](methyl)[(naphthalen-1-yl)methyl]amine
[(E)-6,6-dimethyl-hept-2-en-4-ynyl]-methyl-(naphthalen-1-yl-methyl)-amine
1-NAPHTHALENEMETHANAMINE, N-(6,6-DIMETHYL-2-HEPTEN-4-YNYL)-N-METHYL-, (E)-
161T716
1N,6,6-trimethyl-1N-(1-naphthylmethyl)-(E)-2-hepten-4-yn-1-amine
91161-71-6
A843743
AB0007727
AB00698510_12
AB00698510_13
AB00698510_14
AB00698510-07
AB00698510-09
AB00698510-10
AB00698510-11
AB05470
AB2000250
AC-8561
AC1LU7MZ
AK307954
AKOS001451917
ALBB-027269
AN-1287
AT-6016
BBL010959
BCP22896
BDBM50018518
BIDD:GT0825
BRD-K68132782-003-05-4
BRN 4256376
C08079
CAS-91161-71-6
CCG-221253
CHEBI:9448
CHEBI:94705
CHEMBL822
Corbinal
CS-1944
D02375
DB00857
DOMXUEMWDBAQBQ-WEVVVXLNSA-N
DSSTox_CID_3640
DSSTox_GSID_23640
DSSTox_RID_77123
DTXSID2023640
EC 618-706-8
erbinafine hydrochloride
G7RIW8S0XP
GS-3099
HMS2089B20
HMS3715L08
HY-17395A
K662
KB-50552
Lamasil
Lamasil (TN)
Lamisil
Lamisil AT
Lamisil Tablet
Lamisil;Terbinex;Corbinal;Zabel
LS-94722
MFCD00242672
MLS006011885
MolPort-002-507-761
MolPort-004-637-919
N-[(2E)-6,6-dimethyl-2-hepten-4-yn-1-yl]-N-methyl-1-naphthalenemethanamine
N,6,6-Trimethyl-N-(1-naphthylmethyl)-2-heptene-4-yne-1-amine
N,6,6-trimethyl-N-(1-naphthylmethyl)hept-2-en-4-yn-1-amine hydrochloride
N,6,6-trimethyl-N-(naphthalen-1-ylmethyl)hept-2-en-4-yn-1-amine
NCGC00159346-02
NCGC00159346-03
NCGC00159346-04
NCGC00188975-01
s1725
SBI-0206829.P001
SC-12217
SCHEMBL36794
SCHEMBL37843
SF 86-327
SF-86-327
SF-86327
SMR004703509
STK802069
SW197656-3
terbinafin
Terbinafina
Terbinafine (Lamisil, Terbinex)
Terbinafine (USAN/INN)
Terbinafine [USAN:BAN:INN]
Terbinafine [USAN:INN:BAN]
Terbinafine, SF-86-327, Lamisil, TBNF
Terbinafinum
Terbinex
Tox21_111591
Tox21_111591_1
TX-012572
UNII-G7RIW8S0XP
Zabel
ZINC1530981
Generic filers with tentative approvals for TERBINAFINE
Applicant Application No. Strength Dosage Form
➤ Try a Free Trial➤ Try a Free TrialEQ 250MG BASETABLET; ORAL
➤ Try a Free Trial➤ Try a Free TrialEQ 250MG BASETABLET;ORAL
➤ Try a Free Trial➤ Try a Free TrialEQ 250MG BASETABLET;ORAL

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

US Patents and Regulatory Information for terbinafine

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Aurobindo Pharma TERBINAFINE HYDROCHLORIDE terbinafine hydrochloride TABLET;ORAL 078297-001 Jul 2, 2007 AB RX No No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Taro TERBINAFINE HYDROCHLORIDE terbinafine hydrochloride CREAM;TOPICAL 077511-001 Jul 2, 2007 OTC No No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Cipla TERBINAFINE HYDROCHLORIDE terbinafine hydrochloride TABLET;ORAL 077137-001 Jul 2, 2007 AB RX No No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Glaxosmithkline LAMISIL terbinafine hydrochloride CREAM;TOPICAL 020980-001 Mar 9, 1999 OTC Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Dr Reddys Labs Inc TERBINAFINE HYDROCHLORIDE terbinafine hydrochloride TABLET;ORAL 076390-001 Jul 2, 2007 AB RX No No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Orchid Hlthcare TERBINAFINE HYDROCHLORIDE terbinafine hydrochloride TABLET;ORAL 078163-001 Jul 2, 2007 AB RX No No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

Subscribe to access the full database, or try a Free Trial

Expired US Patents for terbinafine

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Glaxosmithkline Cons LAMISIL AT terbinafine GEL;TOPICAL 021958-001 Jul 24, 2006 ➤ Try a Free Trial ➤ Try a Free Trial
Glaxosmithkline Cons LAMISIL terbinafine GEL;TOPICAL 020846-001 Apr 29, 1998 ➤ Try a Free Trial ➤ Try a Free Trial
Glaxosmithkline Cons LAMISIL terbinafine GEL;TOPICAL 020846-001 Apr 29, 1998 ➤ Try a Free Trial ➤ Try a Free Trial
Glaxosmithkline Cons LAMISIL terbinafine GEL;TOPICAL 020846-001 Apr 29, 1998 ➤ Try a Free Trial ➤ Try a Free Trial
Glaxosmithkline Cons LAMISIL terbinafine GEL;TOPICAL 020846-001 Apr 29, 1998 ➤ Try a Free Trial ➤ Try a Free Trial
Glaxosmithkline Cons LAMISIL terbinafine GEL;TOPICAL 020846-001 Apr 29, 1998 ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Baxter
McKinsey
US Army
Julphar
Farmers Insurance
Teva

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.